Patients with RET+ NSCLC were older at initial diagnosis compared to those with ALK+ or ROS1+ NSCLC (median age: RET: 64 years vs ALK: 51 years, p < 0.001; vs ROS1: 54 years, p = 0.042). The gene discussed is RET; the disease is non-small cell lung carcinoma.